It might be a good time to buy a few NKTR shares. NKTR shares are currently one of the larger positions of my "fund" (see here). There are currently 3830 NKTR shares in the fund with break-even of around 10.78 USD. NKTR is at around $9.17 now.
zzlangerhans on NKTR.
Nektar's recent share price decline comes despite encouraging data for PEGylated irinotecan NKTR-102 in breast cancer and ovarian cancer. The pullback appears to be due to a rebalancing of demand as more conservative biotech investors depart now that the company has declared their intention of proceeding to phase III trials of NKTR-102 without a partner. For the long-term, sales are likely a better strategy than royalties as long as the company is able to manage their debt with a looming repayment deadline in 2012.
The GBMB is not a long-term strategy, so I wouldn't look at Nektar for a real-life buy unless the pullback continued into the single digits.